Niraparib (MK-4827) - Moligand™, 10mM in DMSO , Poly [ADP-ribose] polymerase-1 inhibitor, CAS No.1038915-60-4, Poly [ADP-ribose] polymerase-1 inhibitor

CAS: 1038915-60-4 Cat. No.: N409261 Summenformel: C19H20N4O Molekulargewicht: 320.39 EG-Nummer: 685-112-3
Zu bestellen verfügbar
QUALITÄT & REINHEIT Moligand™ ? Moligand™ — Aladdin's line of ligands and bioactive small molecules. Use for receptor, pathway, and binding studies needing defined small-molecule tools. 10mM in DMSO
Synonyms
(S)-2-(4-(piperidin-3-yl)phenyl)-2H-indazole-7-carboxamide
Storage
Store at -80°C
Shipped In
Dry ice packs + Cold packs
★
Größe
Deutschland (EU)
USA*
Preis
Menge
1ml
N409261-1ml
—
1 Auf Lager
86,69€
Enter a quantity for the sizes you want to add.

Übersicht

Information

Niraparib (MK-4827) is a selective inhibitor ofPARP1/2withIC50of 3.8 nM/2.1 nM, with great activity in cancer cells with mutant BRCA-1 and BRCA-2. It is >330-fold selective against PARP3, V-PARP and Tank1. Niraparib can form PARP–DNA complexes resulting i
In vitro

In a whole cell assay, MK-4827 inhibited PARP activity with EC50 = 4 nM and inhibited proliferation of cancer cells with mutant BRCA-1 and BRCA-2 with CC50 in the 10-100 nM range. It was demonstratedto be a potent and selective PARP-1 and PARP-2 inhibitor with IC50=3.8 and 2.1 nM, respectively. Furthermore, it displayed at least a 100-fold selectivity over PARP-3, V-PARP, and tankyrase-1, with IC50 = 1300, 330, and 570 nM, respectively. As well as inhibiting the growth of HeLa cell lacking BRCA-1 because of silencing by RNA interference, MK-4827 is able to inhibit the proliferation of cancer cell lines carrying natural BRCA-1 or BRCA-2 mutations. In MDA-MB-436 human mammary gland adenocarcinoma cells carrying BRCA-1 mutations, MK-4827 displayed CC50 = 18 nM, while in CAPAN-1 human pancreatic adenocarcinoma cells, which are BRCA-2 mutant, MK-4827 displayed CC50 = 90 nM. In contrast, normal human prostate and mammary epithelial cells are resistant to MK-4827, displaying antiproliferative effects in the micromolar range, thereby demonstrating the very high selective cytotoxicity from these PARP inhibitors in BRCA-1 and -2 mutant cancer cells compared to surrounding tissue.

In vivo

MK-4827, a novel, orally bioavailable, PARP-1 and PARP-2 inhibitor, strongly enhanced the effect of radiation on a variety of human tumor xenografts, both p53 wild type and p53 mutant. It was well tolerated in vivo and demonstrated efficacy as a single agent in a xenograft model of BRCA-1 deficient cancer.
Cell Data

cell lines:Adrenocortical tumor cell line NCI-h295

Concentrations:serial dilutions

Incubation Time:7 days

Powder Purity:≥99%

Spezifikationen

Synonyme
(S)-2-(4-(piperidin-3-yl)phenyl)-2H-indazole-7-carboxamide
Spezifikationen & Reinheit
Moligand™, 10mM in DMSO
Biochemische und physiologische Mechanismen
Niraparib (MK-4827) is a selective inhibitor of PARP1/2 with IC50 of 3.8 nM/2.1 nM, with great activity in cancer cells with mutant BRCA-1 and BRCA-2. It is >330-fold selective against PARP3, V-PARP and Tank1. Niraparib can form PARP–DNA complexes resulting in DNA damage, apoptosis, and cell death. Phase 3.
Storage
Store at -80°C
Verschickt in
Dry ice packs + Cold packs
Dieses Produkt erfordert Kühlkettenversand. Grundversand und andere Economy-Optionen sind nicht verfügbar.
Note
Moligand™
Aktionsart
INHIBITOR
Mechanismus der Wirkung
Poly [ADP-ribose] polymerase-1 inhibitor
Produkteigenschaften
ALogP
2.2
Namen und Kennungen
Isomere SMILES
C1C[C@H](CNC1)C2=CC=C(C=C2)N3C=C4C=CC=C(C4=N3)C(=O)N
Molekulargewicht
320.39
Reaxys
19395275
Reaxys-RN_link_address
https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN=19395275&ln=

Erweiterte Daten

Zugehörige Ziele (menschlich)
TNKS Tchem Tankyrase-1 (1 Activities)
Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)
PARP4 Tchem Poly [ADP-ribose] polymerase 4 (3 Activities)
Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)
PARP3 Tclin Poly [ADP-ribose] polymerase 3 (2 Activities)
Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)
PARP1 Tclin Poly [ADP-ribose] polymerase 1 (15 Activities)
Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)
PARP2 Tclin Poly [ADP-ribose] polymerase 2 (6 Activities)
Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)
PARP12 Tchem Poly [ADP-ribose] polymerase 12 (2 Activities)
Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)
Zertifikate (CoA, COO, BSE/TSE und Analyse-Diagramm)
C of A & Other Certificates(BSE/TSE, COO):
Analytical Chart:
Chemische und physikalische Eigenschaften
LöslichkeitSolubility (25°C) In vitro DMSO: 40 mg/mL (98.22 mM); Ethanol: 3 mg/mL (7.36 mM); Water: Insoluble;
Sicherheit und Gefahren (GHS)
Piktogramm(e)
GHS08,   GHS07
Signal
Danger
Gefahrenhinweise

H373:May causes damage to organs through prolonged or repeated exposure

H302:Harmful if swallowed

H340:May cause genetic defects

H361:Suspected of damaging fertility or the unborn child

Sicherheitshinweise

P280:Wear protective gloves/protective clothing/eye protection/face protection.

P405:Store locked up.

P501:Dispose of contents/container to an approved waste disposal plant.

P264:Wash hands [and …] thoroughly after handling.

P260:Do not breathe dust/fume/gas/mist/vapors/spray.

P281:Use personal protective equipment as required.

P270:Do not eat, drink or smoke when using this product.

P330:Rinse mouth.

P203:Obtain, read and follow all safety instructions before use.

P301+P317:IF SWALLOWED: Get medical help.

P318:if exposed or concerned, get medical advice.

P319:Get medical help if you feel unwell.

Reaxys
19395275
Reaxys-RN_link_address
https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN=19395275&ln=
FAQs und Artikel
Citations of This Product
Lösungsrechner
Bewertungen

Kundenbewertungen

Application Protocols

No vendor-tested biological protocols are provided in the Product Data. The following protocols are general, literature-style examples suitable for research use; optimize for your system.

  • DMSO stock and dilution (general)

    1. Dissolve compound in anhydrous DMSO to 10–50 mM. 2) Aliquot and store at −80 °C. 3) Immediately before use, dilute into pre-warmed assay buffer or culture medium to desired concentration, keeping final DMSO ≤0.1–0.5% v/v.
  • PARP biochemical inhibition assay (illustrative)

    • Prepare reaction buffer (e.g., 50 mM HEPES pH 7.5, 0.5 mM TCEP, 0.01% Tween-20, 5 mM MgCl2). Combine recombinant PARP1/2, activated DNA, and NAD+. Pre-incubate enzyme with inhibitor for 15–30 min at room temperature; initiate with NAD+. Quantify PAR formation by ELISA, radiometric, or fluorescent ADP-ribose detection. Include vehicle and no-enzyme controls.
  • Cell-based target engagement (CETSA example)

    • Treat cells with compound or vehicle for 1–2 h. Harvest and subject aliquots to a temperature gradient. Lyse and analyze PARP1/2 stabilization by immunoblot. Reduced PARylation after DNA damage challenge (e.g., H2O2) can serve as an orthogonal readout.
  • LC–MS reference standard preparation

    • Prepare 1 mg/mL solution in acetonitrile or methanol. Store at −20 to −80 °C in amber vials. Use for calibration curves (serial dilutions) with appropriate internal standards.

All procedures are for research use only. Follow institutional safety practices and SDS guidance.

Biological Roles

Biochemical context for research use; no clinical claims are made.

  • Primary biochemical target (literature)

    • Niraparib is widely reported as a potent, ATP/NAD+-competitive small-molecule inhibitor of poly(ADP-ribose) polymerases PARP1 and PARP2, key enzymes in DNA single-strand break repair via PARylation.
  • Mechanistic features (literature)

    • Binds within the conserved catalytic domain of PARP, mimicking nicotinamide interactions and disrupting ADP-ribose transfer.
    • Inhibition reduces protein PARylation, altering recruitment of DNA repair factors (e.g., XRCC1) and affecting base excision repair signaling cascades in cell-based systems.
  • Cellular/biochemical consequences in research settings (literature)

    • Used to probe DNA damage response pathways, replication stress tolerance, and synthetic-lethality paradigms in vitro.
    • Facilitates studies of chromatin-associated PAR metabolism and interplay with sirtuins and other NAD+-utilizing enzymes (selectivity testing recommended to exclude off-targets).
  • Selectivity considerations (literature)

    • Reported selectivity for PARP1/2 over many other PARP family members; however, family-wide profiling is advisable when pathway specificity is critical. Cellular uptake and efflux transporters can modulate apparent potency.
  • Experimental best practices

    • Employ orthogonal readouts (biochemical activity, CETSA/thermal shift, and PAR ELISA/western PARylation) to confirm on-target effects.
    • Include time-course and washout designs to distinguish acute catalytic inhibition from downstream transcriptional responses.
Buffer Applications

This compound is not a buffer reagent. However, it is frequently dosed into biochemical and cell-based assays prepared in buffered media. Practical guidance is provided for reliable use.

  • Preparing working solutions

    • Prepare concentrated DMSO stocks (e.g., 10–50 mM), then dilute into assay buffer to a final DMSO fraction typically ≤0.1–1% v/v. Add compound last while vortexing to minimize local supersaturation.
    • If aqueous solubility is limiting, consider slight acidification of assay buffer (pH 5–6) when compatible with the biological system, or employ cosolvents (e.g., 0.1–0.5% DMSO with 0.01–0.05% nonionic surfactant such as Tween-20) to reduce aggregation (general practice).
  • Common assay buffers (examples; literature practice)

    • PARP biochemical assays: HEPES or Tris (pH 7.5–8.0), Mg2+, DTT/TCEP, and bovine serum albumin to reduce nonspecific adsorption.
    • Cell culture dosing: dose into complete media with vehicle controls; maintain consistent DMSO across conditions.
  • Handling notes

    • Pre-warm buffers to assay temperature before dilution to reduce precipitation. Mix thoroughly and, if needed, briefly sonicate low-concentration working solutions.
    • Filter through 0.22 µm if particulates are observed; avoid adsorption by pre-conditioning plasticware with buffer containing protein/surfactant.
  • Not applicable aspects

    • pKa-based buffer recipes or buffer capacity calculations are not applicable to this compound, as it is not used to set or maintain pH.
Green Alternatives

As a discrete small-molecule probe, Niraparib itself is not substitutable by a “greener” reagent in the same sense as a solvent. However, greener choices can be made in the way it is handled, formulated, and analyzed.

  • Greener handling/solvent options (general)

    • Prefer aqueous assay buffers with minimal DMSO carryover (≤0.1–0.5% v/v) where compatible.
    • When organic stock solvents are needed, consider ethanol as an alternative to DMSO for low-concentration working solutions if solubility permits.
    • For synthesis or impurity profiling work, replace high-toxicity dipolar aprotics (DMF/NMP) with safer alternatives (e.g., Cyrene, PolarClean) when feasible for analogous scaffolds (literature trend).
  • Analytical method choices

    • Use water-rich LC mobile phases and volatile additives (e.g., formic acid, ammonium formate) to reduce hazardous waste and improve MS compatibility.
    • Scale down assay volumes (miniaturization) to decrease solvent consumption.
  • Small comparison (qualitative)

    • DMSO: excellent solvency; high boiling point complicates waste handling.
    • Ethanol: lower toxicity/biodegradability; may provide insufficient solubility for concentrated stocks.
    • Water (buffered): greenest medium; generally requires cosolvent or pH adjustment to avoid precipitation.
  • Operational tips

    • Use closed, low-dead-volume systems to limit evaporative losses.
    • Consolidate washes and segregate halogen-free organic waste to facilitate downstream treatment.

These considerations target the process footprint around the compound rather than altering the compound itself.

Pharmaceutical Uses

This product is supplied strictly for research use and not for human or veterinary applications. No clinical or therapeutic claims are made.

  • Research/formulation context

    • In preclinical method development, Niraparib can serve as a reference standard or system suitability compound for analytical methods (e.g., LC–UV/LC–MS) targeting PARP inhibitor panels.
    • For in vitro ADME studies (non-GLP), it may be used as a control compound to benchmark permeability, metabolic stability, and protein binding protocols (laboratory research only).
  • Excipient status and pharmacopeia

    • Not an excipient; no pharmacopeial monograph is cited here. Any pharmaceutical-grade specifications are Not specified for this item; refer to CoA/Spec Sheet.
  • Formulation notes for research

    • Stock solutions are typically prepared in DMSO and diluted into aqueous media immediately before use. Salt formation (e.g., hydrochloride, tosylate) can enhance aqueous solubility for certain research applications; confirm identity and counterion content analytically if salts are prepared in-house.
  • Compliance

    • This item is provided for laboratory research use only. It is not intended for diagnostic procedures, clinical applications, or for use in foods, cosmetics, or household products.
Physical Properties

Item-specific physicochemical specifications are not provided in the Product Data; consult the CoA/Spec Sheet for definitive values.

  • Item-specific values

    • Appearance: Not specified for this item; refer to CoA/Spec Sheet.
    • Molecular formula: Not specified for this item; refer to CoA/Spec Sheet.
    • Molecular weight: Not specified for this item; refer to CoA/Spec Sheet.
  • Literature/general reference values (verify for your lot)

    • Molecular formula (free base): C19H20N4O (literature)
    • Molecular weight (free base): ~320.39 g/mol (literature)
    • Physical state: typically a solid at ambient conditions (literature)
    • Solubility: commonly formulated as DMSO stock solutions (e.g., 10–50 mM); sparingly soluble in aqueous buffers without cosolvent or acidification (literature). Soluble in polar aprotic organic solvents such as DMSO and DMF; limited solubility in methanol/ethanol; negligible in alkanes (literature, qualitative).
    • pKa: expected basic pKa in the range typical for tertiary amines (piperidines) enabling salt formation with mineral/organic acids (literature, qualitative).
    • LogP/LogD: consistent with drug-like, moderately lipophilic heteroaromatic scaffolds; actual value should be taken from a trusted database if required for modeling (literature, qualitative).
  • Practical handling notes (general)

    • Prepare concentrated DMSO stock, then dilute into assay buffer with final DMSO ≤0.1–1% v/v to minimize compound precipitation and solvent effects (literature practice).
    • Consider gentle heating (≤40 °C) and/or brief sonication to assist dissolution in DMSO; filter through 0.22 µm PTFE if particulates persist.
Quality and Grades

This product is offered as Moligand™ grade within a small-molecule/compound library context, intended for research screening and discovery workflows.

  • What Moligand™ typically implies (general description)

    • Designed for ligand discovery, HTS, and profiling: emphasis on identity confirmation and suitability for biochemical/cellular assays.
    • Purity and analytical controls prioritize performance in screening; UV cutoff, residual solvents, water content, metals, and stabilizers are managed to typical discovery standards but are not specified here. For lot-specific limits, consult the CoA/Spec Sheet.
  • Item-specific information (from Product Data)

    • Grade/Purity designation: Moligand™ (no numeric purity provided).
    • Stabilizers/additives: Not specified for this item; refer to CoA/Spec Sheet.
    • Appearance: Not specified for this item; refer to CoA/Spec Sheet.
  • Practical implications

    • Suitable for: biochemical target engagement assays, PARP enzymology, cell-based phenotypic screens, and as a reference control in DNA-damage pathway studies.
    • Not intended for: clinical use, diagnostic procedures, or GMP manufacturing. For research use only (Product Data).
  • Documentation

    • For each lot, request the CoA/Spec Sheet for: analytical identity (e.g., HRMS, NMR), purity (HPLC/UPLC), residual solvent profile, and recommended handling. Where applicable, chromatographic traces and spectral copies are often provided for screening-grade compounds.
Reaction and Applications

This product is primarily used as a research tool compound and reference standard rather than as a general reagent; nevertheless, it enables a range of discovery and analytical applications.

  • Research applications (from catalog context; expanded)

    • Chemical probe for PARP enzymology: supports studies of poly(ADP-ribose) polymerase catalytic activity and NAD+-competitive inhibition in biochemical assays (literature context).
    • Cellular pathway interrogation: modulation of DNA damage response signaling, facilitating synthetic-lethality research frameworks in vitro (literature; non-clinical).
    • Screening workflows: serves as a positive control in high-content imaging, target engagement (e.g., CETSA/thermal shift), and biochemical HTS/SPR/biophysical assays.
    • Analytical use: calibration/retention-time marker in LC/LC–MS methods for PARP inhibitor panels; internal/external standard for method qualification (non-GMP).
  • Derivatization/SAR (general chemistry)

    • The scaffold tolerates modifications at the carboxamide (acyl replacement), at the piperidine nitrogen (N-alkylation, salt formation), and on the aryl/indazole rings (electrophilic substitution or cross-coupling when appropriately functionalized). Such transformations support structure–activity relationship campaigns (literature guidance).
  • Practical notes

    • Prepare and store DMSO master stocks under inert headspace when feasible; avoid repeated freeze–thaw.
    • For biochemical assays, pre-incubate with enzyme to ensure equilibrium binding; include matched vehicle controls.
    • Verify target engagement orthogonally (e.g., enzymatic IC, thermal stabilization, or binding assays) to de-risk assay artifacts.

All uses are for research purposes only; no clinical or diagnostic applications are implied.

Reaction Conditions

This section provides general literature-style guidance relevant to modifying or using compounds of this class; it is not a specification for this item.

  • Stock solution preparation (common laboratory practice)

    • Dissolve in anhydrous DMSO to 10–50 mM under ambient conditions with gentle warming (≤40 °C) and sonication as needed. Store aliquots at −20 to −80 °C; avoid repeated freeze–thaw.
  • Representative transformations on related scaffolds (general)

    • Amide coupling: HATU/EDC·HCl with DIPEA in DMF or MeCN, 0–25 °C, 1–16 h, furnishing amide analogs in typical 60–90% isolated yields (literature, reaction-class benchmarks).
    • N-alkylation of piperidine: alkyl halide (1.1–1.5 eq), K2CO3 or DIPEA, MeCN/DMF, 20–60 °C, 2–12 h. Monitor to avoid over-alkylation; quaternization if desired.
    • Aromatic N-arylation (if applicable intermediates): Buchwald–Hartwig using Pd2(dba)3/XPhos or BrettPhos, NaOtBu, toluene or dioxane, 80–110 °C, 6–18 h (literature precedent for indazole/aryl couplings).
  • Assay incubation conditions (biochemical, literature)

    • PARP enzymatic assays often run at pH 7.5–8.0, 25–30 °C, with NAD+ and activated DNA; inhibitor preincubation 10–30 min prior to initiation improves equilibration. Final DMSO ≤1% v/v.
  • Analytical conditions (typical)

    • LC–MS: C18 column, water/acetonitrile + 0.1% formic acid gradient; ESI+ detection for amine-containing analytes. Retention and ionization depend on mobile phase and column selection.

These are general conditions for comparable chemotypes and applications; adapt based on your system and confirm experimentally.

Safety and Handling

Safety information specific to this item is not fully specified in the Product Data. Always consult the SDS for authoritative guidance and institutional policies.

  • Item-specific guidance

    • Storage: Store at −80 °C (Product Data).
    • Shipping: Dry ice packs + cold packs (Product Data).
  • GHS classification and hazard statements

    • Signal word: Not specified for this item; refer to SDS.
    • H-statements, pictograms, GHS class: Not specified for this item; refer to SDS.
  • General laboratory precautions (good practice for small-molecule research compounds)

    • PPE: laboratory coat, nitrile gloves, and safety glasses; handle powders in a fume hood to avoid inhalation exposure.
    • Avoid skin/eye contact and inhalation of dust or aerosols. Prevent ingestion. Wash thoroughly after handling.
    • Incompatibilities: Strong oxidizers and strong acids/bases may lead to degradation; avoid prolonged exposure to light, heat, and moisture (general small-molecule guidance).
    • First aid (overview; defer to SDS): In case of eye/skin contact, rinse with water for several minutes; remove contaminated clothing. If inhaled, move to fresh air. If ingested or if symptoms occur, seek medical attention.
  • Waste disposal

    • Dispose of unused material and solutions as organic hazardous waste according to local regulations. Quench or neutralization is generally not applicable; avoid drain disposal.
  • Special risks/notes

    • As an amine-containing heteroaromatic, it may form salts with acids; avoid unintended exposure to acidic vapors. Use amber containers if prolonged light exposure is expected.
Solvent Selection

Niraparib is a heteroaromatic amide with a basic piperidine; solubility behavior is typical of neutral/weakly basic drug-like molecules.

  • Polarity and miscibility (literature, general)

    • Preferred stock solvent: DMSO (high solubility; stable for aliquoted frozen stocks).
    • Alternative solvents: DMF and NMP (good solvating power), with ethanol or methanol providing limited solubility for dilute working solutions.
    • Aqueous solubility: low at neutral pH without cosolvent; can be improved by acidifying buffer (e.g., to pH 3–5) to form protonated species (literature practice). Use caution with biological assay compatibility.
  • Practical selection by application

    • Biochemical assays: prepare concentrated DMSO stock (e.g., 10–50 mM) and dilute into assay buffer to a final DMSO fraction ≤0.1–1% v/v to minimize solvent effects.
    • Cell-based assays: DMSO vehicle at ≤0.1–0.5% v/v is commonly tolerated; perform vehicle controls and gradual titration to prevent precipitation.
    • Analytical prep (HPLC): dissolve in acetonitrile or methanol; use aqueous mobile phases containing 0.1% formic acid or ammonium formate for LC-MS compatibility (literature practice).
  • Quick comparison (general)

    • DMSO: highest solvency; best for concentrated stocks; higher boiling point and viscosity.
    • DMF/NMP: similar solvency; consider toxicity and hygroscopicity.
    • Alcohols: moderate solvency; useful for lower concentrations and easier evaporation.
    • Water/buffers: require cosolvent or pH adjustment; watch for precipitation on dilution.
  • Tips

    • Warm and vortex/sonicate to aid dissolution; filter through 0.22 µm PTFE if needed. Pre-equilibrate solutions to assay temperature to avoid out-of-solution events.
Storage and Reconstitution

Item-specific storage and shipping conditions are provided; additional best practices are included for robust performance in research workflows.

  • Item-specific conditions (from Product Data)

    • Storage: Store at −80 °C.
    • Shipped in: Dry ice packs + cold packs.
  • Reconstitution (general guidance)

    • Solvent: Use anhydrous DMSO to prepare concentrated stock solutions (e.g., 10–50 mM). If lower DMSO is desired, consider DMF or ethanol as secondary options where solubility allows.
    • Technique: Allow vial to equilibrate to room temperature in a desiccated environment before opening to prevent moisture condensation. Add solvent, vortex, and gently sonicate if needed. Filter through a 0.22 µm PTFE membrane if particulates persist.
    • Aliquoting: Dispense into small, inert vials or tubes (amber recommended) to minimize freeze–thaw cycles. Backfill headspace with inert gas if long-term storage is planned.
  • Storage of solutions

    • Short term (days to weeks): −20 °C for DMSO stocks, protected from light.
    • Long term (weeks to months): −80 °C for DMSO stocks, protected from light. Avoid repeated freeze–thaw by using single-use aliquots.
  • Stability and specifications

    • Appearance, stabilizers, and exact solution stability: Not specified for this item; refer to CoA/Spec Sheet.
    • Always inspect solutions for precipitation or discoloration before use; discard if anomalies are observed.
  • Research use note

    • For research use only; not for human or veterinary use.
Structure and Identity

Concise identity and structural overview for professional users.

  • Item-specific identifiers (from Product Data)

    • Product name: Niraparib (MK-4827)
    • SKU: N409261
    • CAS: 1038915-60-4
    • PubChem CID: 24958200
    • Grade: Moligand™
    • InChIKey: Not specified for this item; refer to CoA/Spec Sheet.
    • SMILES: Not specified for this item; refer to CoA/Spec Sheet.
  • Literature structural information (for reference only; verify against CoA)

    • Common scaffold: 2-arylindazole bearing a carboxamide function and a para-phenyl substituent carrying a piperidin-3-yl moiety.
    • Typical functional groups: indazole (fused diazole heteroaromatic), primary carboxamide (–CONH2), tertiary aliphatic amine (piperidine nitrogen), and two aromatic rings (indazole and phenyl) connected through the indazole N1–aryl linkage.
    • Molecular formula (free base, literature): C19H20N4O
    • Molecular weight (free base, literature): ~320.39 g/mol
    • Stereochemistry: Some sources depict a 3-substituted piperidine which can define a stereocenter; commercial materials may be racemic unless otherwise specified. This item’s stereochemical specification is not provided in the Product Data.
  • 2D structural description (general)

    • An indazole core substituted at the 7-position with a carboxamide, N1 of the indazole bonded to a para-substituted phenyl ring. The para substituent is a piperidin-3-yl group (saturated six-membered ring containing one tertiary amine). The molecule is largely rigid across the biaryl/indazole domain with added conformational flexibility from the piperidine ring.
Synthetic Utility

While primarily a finished probe compound, the Niraparib scaffold offers handles for chemical modification in medicinal chemistry and analytical derivatization.

  • Functional groups and reactivity (general)

    • Carboxamide (–CONH2): amenable to acyl replacement, conversion to ureas/thioureas, or late-stage activation (e.g., to acid chlorides after hydrolysis if an acid precursor is available). Stable to mild bases and acids; susceptible to strong dehydrating conditions.
    • Indazole core: electrophilic substitution possible at activated positions; N1 is typically substituted by the aryl in Niraparib. Metalation or cross-coupling requires appropriately prefunctionalized intermediates (e.g., bromo/iodo aryl partners in retrosynthesis).
    • Piperidine nitrogen: can undergo N-alkylation/acylation to tune basicity and solubility; quaternization yields permanently charged analogs for probe development.
  • Retrosynthetic motifs (literature, general)

    • Assembly of the 2-arylindazole often proceeds via cyclization of o-hydrazonyl derivatives or N–N bond formation on substituted anilines, followed by N-arylation (e.g., Buchwald–Hartwig) to install the biaryl linkage.
    • Installation of the piperidin-3-yl substituent classically employs cross-coupling or nucleophilic aromatic substitution on a para-activated aryl precursor, or reductive amination to access the 3-substituted piperidine intermediate.
  • Applications

    • Generation of SAR analogs for PARP binding pocket exploration (nicotinamide-mimetic space).
    • Preparation of labeled standards (e.g., stable isotope or fluorescent tags) for bioanalytical method development.

Note: The above describes general synthetic logic for related scaffolds; it is not a lot-specific manufacturing route.

Target Specificity

This section is adapted for a small-molecule probe (not an antibody). Information below reflects literature knowledge and should be validated in your system; no clinical claims are made.

  • Intended research target

    • Poly(ADP-ribose) polymerases PARP1 and PARP2 (literature): catalytic domain inhibitors competing with NAD+/nicotinamide binding.
  • Selectivity notes (literature)

    • Frequently reported to preferentially inhibit PARP1/2 among PARP family members; off-target profiling against a broader enzyme/receptor panel is recommended for mechanistic studies.
    • Cellular context (efflux, uptake, protein binding) can influence apparent selectivity and potency; include appropriate controls (time- and concentration-matched vehicle, inactive analogs, or rescue experiments).
  • Orthogonal verification

    • Use multiple assay modalities: biochemical IC determination, thermal shift (CETSA/DSF) showing target stabilization, and immunoassays tracking global PARylation reduction after DNA damage induction.
  • Not applicable (antibody-specific metadata)

    • Clone, isotype, species reactivity, and epitope mapping are not applicable to this small-molecule product and are therefore not provided.

Häufig gestellte Fragen

What is Moligand??
Moligand? is one of Aladdin Scientific's premium product lines, formulated for high-purity applications across multiple workflows. Compared to standard grades in the same workflow, Moligand? products typically offer tighter specifications, more rigorous QC, and stronger lot-to-lot consistency.
How should this product be stored?
Store at ?80 °C. Ultra-low temperature storage is required to maintain the specified shelf life.
How is this product shipped?
This product ships frozen with dry ice and cold packs. Unpack on arrival and transfer it to the storage condition stated above; handle dry ice with insulated gloves in a ventilated area.
What are the CAS number, molecular formula and molecular weight?
The CAS Number is 1038915-60-4, the molecular formula is C19H20N4O, and the molecular weight is 320.39 g/mol.
What documentation is provided?
Available product documentation, including Certificates of Analysis (COA), Safety Data Sheets (SDS), and specification sheets, is shown in the product document area. Document availability and access follow the current site policy.

Benötigen Sie Hilfe bei der Auswahl der Qualität?

Unser Leitfaden zur Qualitätsauswahl behandelt Reinheit, Stabilisatorstatus und Anwendungseignung für alle Varianten in unserem Katalog.

Moligand™ Qualitätsleitfaden ansehen →

Dürfen wir Sie über Rabattaktionen informieren?

Später erinnern

Vielen Dank! Bitte überprüfen Sie Ihren E-Mail-Posteingang, um zu bestätigen.

Hoppla! Benachrichtigungen sind deaktiviert.